COSELA (trilaciclib) for the Treatment of Chemotherapy-Induced Myelosuppression – Clinical Trials Arena

COSELA is the first myeloprotection therapy indicated to reduce the incidence of chemotherapy-induced myelosuppression in adult patients. Credit: G1 Therapeutics. Small cell lung cancer represents nearly 10% to 15% of all lung cancer cases. Credit: BonD80 / Shutterstock. Trilaciclib is a competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6). Credit: StudioMolekuul / Shutterstock.

COSELA (trilaciclib) is the first approved myeloprotection therapy indicated to reduce the occurrence of chemotherapy-induced bone marrow suppression in adult patients.

Developed by G1 Therapeutics (GTHX), a US-based clinical-stage biopharmaceutical company, the drug is available in a single-dose vial as a sterile, preservative-free, yellow lyophilised cake in a 300mg dosage strength for intravenous administration.

In June 2020, G1 Therapeutics signed a three-year co-promotion agreement with German pharmaceutical firm Boehringer Ingelheim (BI) to jointly promote trilaciclib for the treatment of small cell lung cancer in the US and Puerto Rico.

Under the agreement, G1 Therapeutics will lead marketing, market access and medical engagement initiatives for COSELA while Boehringer Ingelheim will undertake salesforce engagements.

In August 2020, China-based Simcere Pharmaceutical Group was granted the development and commercialisation rights of the drug in all indications for Greater China.

The New Drug Application (NDA) for trilaciclib was submitted to the US Food and Drug Administration (FDA) in June 2020 and granted priority review in August 2020.

In February 2021, the FDA approved trilaciclib to reduce chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients, prior to chemotherapy treatments involving platinum-etoposide or topotecan options. The FDA also bestowed breakthrough therapy designation to trilaciclib in August 2019.

Myelosuppression, also known as bone marrow suppression, is a chemotherapy-induced bone marrow damage condition that lowers blood cell production.

Although chemotherapy drugs are used to destroy cancer cells, they can also cause damage to healthy cells in the bone marrow such as hematopoietic stem and progenitor cells (HSPCs), which produce white blood cells, red blood cells and platelets.

Myelosuppression is a side effect of chemotherapy and occurs when the hematopoietic stem and progenitor cells are damaged by chemotherapy treatment, thereby suppressing the ability of bone marrow to produce blood cells.

The common symptoms associated with myelosuppression include fatigue, shortness of breath, and dizziness. Myelosuppression can also lead to serious blood cell diseases such as anaemia, neutropenia and thrombocytopenia.

Trilaciclib is a transient and competitive inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). The drug delivers a myeloprotective therapy against chemotherapy-induced bone marrow suppression by inhibiting CDK4/6 that regulates cell cycle.

By inhibiting CDK4/6, trilaciclib temporarily and reversibly induces G1 cell cycle arrest in hematopoietic stem and progenitor cells (HSPCs) and prevents transition to the synthesis phase (S phase) of cell cycle, thus protecting the HSPCs from the damaging effects of chemotherapy and maintaining the normal function of the bone marrow.

COSELAs FDA approval was based on the outcome of three randomised, double-blind, placebo-controlled clinical trials in patients with extensive-stage small cell lung cancer. The effectiveness of drug was evaluated in combination with carboplatin-etoposide, with or without atezolizumab and topotecan chemotherapy.

The studies randomly enrolled 245 patients to receive either intravenous (IV) trilaciclib or placebo prior to the start of chemotherapy.

The primary endpoints of the studies were the percentage of patients with severe neutropenia and its duration during the first chemotherapy cycle.

The trials demonstrated clinical reduction in the duration and severity of neutropenia among ES-SCLC patients who received trilaciclib before chemotherapy.

A positive impact on red blood cell transfusions and other myeloprotective measures was also observed.

The most frequent side effects observed in the patients during the clinical trials were fatigue, hypophosphatemia, hypocalcaemia, hypokalaemia, headache, high aspartate aminotransferase levels and pneumonia. More than 3% of the patients who received COSELA experienced serious adverse reactions, including respiratory failure, haemorrhage and thrombosis.

See the original post:

COSELA (trilaciclib) for the Treatment of Chemotherapy-Induced Myelosuppression - Clinical Trials Arena

Read more
The North America organoids market is expected to reach US$ 1,406.47 million by 2027 from US$ 291.39 million in 2019 – Yahoo Finance


Never say that one person makes no difference. This past Thursday, stocks tumbled, bonds surged, and investors started taking inflationary risks seriously all because one guy said what he thinks. Jerome Powell, chair of the Federal Reserve, held a press conference at which he gave both the good and the bad. He stated, again, his belief that the COVID vaccination program will allow a full reopening of the economy, and that well see a resurgence in the job market. Thats the good news. The bad news, well also likely see consumer prices go up in the short term inflation. And when inflation starts rising, so do interest rates and thats when stocks typically slide. Were not there yet, but the specter of it was enough this past week to put serious pressure on the stock markets. However, as the market retreat has pushed many stocks to rock-bottom prices, several Wall Street analysts believe that now may be the time to buy in. These analysts have identified three tickers whose current share prices land close to their 52-week lows. Noting that each is set to take back off on an upward trajectory, the analysts see an attractive entry point. Not to mention each has earned a Moderate or Strong Buy consensus rating, according to TipRanks database. Alteryx (AYX) Well start with Alteryx, an analytic software company based in California that takes advantage of the great changes brought by the information age. Data has become a commodity and an asset, and more than ever, companies now need the ability to collect, collate, sort, and analyze reams of raw information. This is exactly what Alteryxs products allow, and the company has built on that need. In Q4, the company reported net income of 32 cents per share on $160.5 million in total revenues, beating consensus estimates. The company reported good news on the liquidity front, too, with $1 billion in cash available as of Dec 31, up 2.5% the prior year. In Q4, operating cash flow reached $58.5 million, crushing the year-before figure of $20.7 million. However, investors were wary of the lower-than-expected guidance. The company forecasted a range of between $104 million to $107 million in revenue, compared to $119 million analysts had expected. The stock tumbled 16% after the report. That was magnified by the general market turndown at the same time. Overall, AYX is down ~46% over the past 52 months. Yet, the recent sell-off could be an opportunity as the business remains sound amid these challenging times, according to 5-star analyst Daniel Ives, of Wedbush. We still believe the company is well positioned to capture market share in the nearly ~$50B analytics, business intelligence, and data preparation market with its code-friendly end-to-end data prep and analytics platform once pandemic pressures subside. The revenue beat was due to a product mix that tilted towards upfront revenue recognition, an improvement in churn rates and an improvement in customer spending trends," Ives opined. Ives comments back his Outperform (i.e. Buy) rating, and his $150 price target implies a one-year upside of 89% for the stock. (To watch Ives track record, click here) Overall, the 13 analyst recent reviews on Alteryx, breaking down to 10 Buys and 3 Holds, give the stock a Strong Buy analyst consensus rating. Shares are selling for $79.25 and have an average price target of $150.45. (See AYX stock analysis on TipRanks) Root, Inc. (ROOT) Switching over to the insurance sector, well look at Root. This insurance company interacts with customers through its app, acting more like a tech company than a car insurance provider. But it works because the way customers interact with businesses is changing. Root also uses data analytics to set rates for customers, basing fees and premiums on measurable and measured metrics of how a customer actually drives. Its a personalized version of car insurance, fit for the digital age. Root has also been expanding its model to the renters insurance market. Root has been trading publicly for just 4 months; the company IPO'd back in October, and its currently down 50% since it hit the markets. In its Q4 and Full-year 2020 results, Root showed solid gains in direct premiums, although the company still reports a net loss. For the quarter, the direct earnings premiums rose 30% year-over-year to $155 million. For all of 2020, that metric gained 71% to reach $605 million. The full-year net loss was $14.2 million. Truist's 5-star analyst Youssef Squali covers Root, and he sees the company maneuvering to preserve a favorable outlook this year and next. ROOT's mgt continues to refine its growth strategy two quarters post IPO, and 4Q20 results/2021 outlook reflects such a process... They believe their stepped-up marketing investment should lead to accelerating policy count growth as the year progresses and provide a substantial tailwind heading into 2022. To us, this seems part of a deliberate strategy to marginally shift the balance between topline growth and profitability slightly more in favor of the latter, Squali noted. Squalis rating on the stock is a Buy, and his $24 price target suggests a 95% upside in the months ahead. (To watch Squalis track record, click here) Shares in Root are selling for $12.30 each, and the average target of $22 indicates a possible upside of ~79% by years end. There are 5 reviews on record, including 3 to Buy and 2 to Hold, making the analyst consensus a Moderate Buy. (See ROOT stock analysis on TipRanks) Arco Platform, Ltd. (ARCE) The shift to online and remote work hasnt just impacted the workplace. Around the world, schools and students have also had to adapt. Arco Platform is a Brazilian educational company offering content, technology, supplemental programs, and specialized services to school clients in Brazil. The company boasts over 5,400 schools on its client list, with programs and products in classrooms from kindergarten through high school and over 405,000 students using Arco Platform learning tools. Arco will report 4Q20 and full year 2020 results later this month but a look at the companys November Q3 release is instructive. The company described 2020 as a testament to the resilience of our business. By the numbers, Arco reported strong revenue gains in 2020 no surprise, considering the move to remote learning. Quarterly revenue of 208.7 million Brazilian reals (US$36.66 million) was up 196% year-over-year, while the top line for the first 9 months of the year, at 705.2 million reals (US$123.85 million) was up 117% yoy. Earnings for educational companies can vary through the school year, depending on the school vacation schedule. The third quarter is typically Arcos worst of the year, with a net loss and 2020 was no exception. But, the Q3 net loss was only 9 US cents per share a huge improvement from the 53-cent loss reported in 3Q19. Mr. Market chopped off 38% of the companys stock price over the past 12 months. One analyst, however, thinks this lower stock price could offer new investors an opportunity to get into ARCE on the cheap. Credit Suisse's Daniel Federle rates ARCE an Outperform (i.e. Buy) along with a $55 price target. This figure implies a 12-month upside potential of ~67%. (To watch Federles track record, click here) Federle is confident that the company is positioned for the next leg of growth, noting: "[The] company is structurally solid and moving in the right direction and... any eventual weak operating data point is macro related rather than any issue related to the company. We continue with the view that growth will return to its regular trajectory once COVID effects dissipate. Turning to expansionary plans, Federle noted, Arco mentioned that it is within their plans to launch a product focused on the B2C market, likely already in 2021. The product will be focused on offering courses (e.g. test preps) directly to students. It is important to note that this product will not be a substitute for learning systems, rather a complement. Potential success obtained in the B2C market is an upside risk to our estimates. There are only two reviews on record for Arco, although both of them are Buys, making the analyst consensus here a Moderate Buy. Shares are trading for $33.73 and have an average price target of $51, which suggests a 51% upside from that level. (See ARCE stock analysis on TipRanks) To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

The rest is here:

The North America organoids market is expected to reach US$ 1,406.47 million by 2027 from US$ 291.39 million in 2019 - Yahoo Finance

Read more
Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine…

PHOENIX, March 4, 2021 /PRNewswire/ --(OTC - CELZ)Creative Medical Technology Holdings announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation perispinal injection of bone marrow cells in patients with disc degenerative disease. Evaluation of patients at 30,60 90, 180, and 360 days revealed significant improvement in mobility and reduction in pain score . The mean pain changed from 8.9 at baseline to 4.3 at 30 days and sustained to 1.8 at 6 months and 1.3 at 12 months with a gradual reduction in overall pain medication utilization guided by their healthcare team. No serious adverse effects were noted with some short-term bruising in two patients at the harvest site and no long term adverse events where reported related to the procedure.

"This publication, which is "pre-peer review" describes what to our knowledge is the first demonstration of a signal of clinical efficacy by injecting stem cells in areas surrounding the disc." Said Dr Amit Patel, Board Member and Co-Founder of the Company. "While others have intra-disc injection may help disc pain, the current work regenerates the blood supple to the disc, allowing the disc to heal itself."

The autologous utilization of bone marrow falls under the "minimal manipulation exception" and can be commercialized rapidly, in the same manner that the Company commercialized Caverstem for treatment of erectile dysfunction.

Granted United States Patent #9,598,673 which is owned by the Company covers the use of any mesenchymal stem cells, both from the patient or from donors, for reduction of lower back pain when injected into the major muscles of the lower back.

"Disc degenerative disease represents a multi-billion dollar market for which current medical solutions do not address the underlying cause, while surgery is expensive and not applicable for a significant number of patients." Said Timothy Warbington, President and CEO of the Company. "We are excited to follow the path we did with CaverStem and initiate commercialization of this technology for American patients."

To view our Publication:

About Creative Medical Technology HoldingsCreative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the ticker symbol CELZ. For further information about the company, please

Forward Looking StatementsOTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website

SOURCE Creative Medical Technology Holdings, Inc.


Follow this link:

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine...

Read more
Combined livercytokine humanization comes to the rescue of circulating human red blood cells – Science

A red-letter day for RBC research

The study of primary human red blood cell (huRBC) disorders such as sickle cell disease (SCD) and infectious diseases such as malaria has been hampered by a lack of in vivo models of human erythropoiesis. Song et al. transferred human fetal liver cells into MISTRG mice, which are immunodeficient and are genetically engineered with several human genes involved in hematopoiesis. This approach was unsuccessful because mature huRBCs are rapidly destroyed in the mouse liver. They then used CRISPR-Cas9 to mutate these mice into a fumarylacetoacetate hydrolasedeficient strain, allowing them to replace the mouse liver with engrafted human hepatocytes. These mice exhibited enhanced human erythropoiesis and circulating huRBC survival and could recapitulate SCD pathology when reconstituted with SCD-derived HSCs.

Science, this issue p. 1019

In vivo models that recapitulate human erythropoiesis with persistence of circulating red blood cells (RBCs) have remained elusive. We report an immunodeficient murine model in which combined human liver and cytokine humanization confer enhanced human erythropoiesis and RBC survival in the circulation. We deleted the fumarylacetoacetate hydrolase (Fah) gene in MISTRG mice expressing several human cytokines in place of their murine counterparts. Liver humanization by intrasplenic injection of human hepatocytes (huHep) eliminated murine complement C3 and reduced murine Kupffer cell density. Engraftment of human sickle cell disease (SCD)derived hematopoietic stem cells in huHepMISTRGFah/ mice resulted in vaso-occlusion that replicated acute SCD pathology. Combined livercytokinehumanized mice will facilitate the study of diseases afflicting RBCs, including bone marrow failure, hemoglobinopathies, and malaria, and also preclinical testing of therapies.

See original here:

Combined livercytokine humanization comes to the rescue of circulating human red blood cells - Science

Read more
Global Biobanks Markets Report 2021-2028: Biobanks Continue to Evolve with New Technologies Such as NGS and Increased Focus on Genomic Medicine -…

DUBLIN, March 2, 2021 /PRNewswire/ -- The "Biobanks Market Size, Share & Trends Analysis Report by Product, by Service (Cold Chain, Lab Processing), by Biospecimen Type, by Biobank Type (Virtual, Physical), by Application, by Region, and Segment Forecasts, 2021 - 2028" report has been added to's offering.

The global biobanks market size is expected to reach USD 106.9 billion by 2028 and is expected to expand at a CAGR of 6.2% from 2021 to 2028.

Biobanks continue to evolve with the introduction of new technologies such as NGS and increased focus on genomic medicine. The availability of several types of biospecimens to cater to multiple domains including drug discovery, diagnostics, and others has accelerated the diversification of biorepositories, thereby driving the market.

The quality of biospecimens can significantly influence the disease testing as well as preclinical and clinical research. Regulatory agencies have played a vital role in spurring the adoption of biobanking services by establishing guidelines for the effective management of samples. For instance, the U.S. Centers for Disease Control and Prevention (CDC) released guidelines to minimize human hazards while handling COVID-19 samples.

This serves as a model for other biorepositories. Furthermore, as the number of research studies and clinical trials related to COVID-19 is increasing, the demand for high-quality biospecimens is expected to significantly increase in the near future, leading to market growth. In addition, population-based cohort studies are facilitated by biorepositories to estimate the actual seroprevalence.

Health Catalyst, Inc., through its Touchstone platform, provides national data related to COVID-19 insights. Such factors are anticipated to contribute to the revenue flow in this space.

Biobanks Market Report Highlights

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Outlook3.1 Market Dynamics3.1.1 Market driver analysis3.1.1.1 Continuous increase in COVID-19 cases3.1.1.2 Increased focus on precision medicine and genetic testing3.1.1.3 Changes in biobanking operations3.1.1.4 Increase in the number of clinical trials globally3.1.1.5 Growing industry and research collaborations3.1.1.6 Technology advancement and automation3.1.2 Market restraint analysis3.1.2.1 Disruptions in supply chain management due to COVID- Challenges in sharing biobanking data & limited access to biospecimens3.1.2.3 Sustainability challenges for biobanks3.1.2.4 Other challenges in biobanking specimens for research3.2 Penetration & Growth Prospect Mapping for Services, 20203.3 Biobanks Market - Regulatory Framework3.3.1 Regulatory Landscape, U.S.3.3.2 Regulatory Landscape, Canada3.3.3 Regulatory Landscape, Europe3.3.4 Regulatory Landscape, China3.3.5 Regulatory Landscape, Japan3.3.6 List of Factors/Regulations/Nature of Governments, by Country3.4 Biobanks Market - Porter's Analysis3.5 Biobanks Market - SWOT Analysis

Chapter 4 Biobanks Market Categorization: Products Estimates & Trend Analysis4.1 Global Biobanks Market: Products Movement Analysis, 2020 & 20284.2 Biobanking Equipment4.2.1 Global biobanking equipment market, 2017 - 2028 (USD Million)4.2.2 Temperature control systems4.2.2.1 Global biobanking temperature control systems market, 2017 - 2028 (USD Million) Freezers & refrigerators4.2.2.3 Cryogenic storage systems4.2.2.4 Thawing equipment4.2.3 Incubators & centrifuges4.2.4 Alarms & monitoring systems4.2.5 Accessories & other equipment4.3 Biobanking Consumables4.4 Laboratory Information Management Systems (LIMS)

Chapter 5 Biobanks Market Categorization: Services Estimates & Trend Analysis5.1 Global Biobanks Market: Services Movement Analysis, 2020 & 20285.2 Biobanking & Repository5.3 Lab Processing5.4 Qualification/ Validation5.5 Cold Chain Logistics

Chapter 6 Biobanks Market Categorization: Biospecimen Types Estimates & Trend Analysis6.1 Global Biobanks Market: Biospecimen Types Movement Analysis, 2020 & 20286.2 Human Tissues6.3 Human Organs6.4 Stem Cells6.4.1 Global stem cell biobanking market, 2017 - 2028 (USD Million)6.4.2 Adult stem cells6.4.3 Embryonic stem cells6.4.4 Induced Pluripotent Stem (IPS) Cells6.4.5 Other Stem Cells6.5 Other Biospecimens

Chapter 7 Biobanks Market Categorization: Biobank Types Estimates & Trend Analysis7.1 Global Biobanks Market: Biobank Types Movement Analysis, 2020 & 20287.2 Physical/Real Biobanks7.2.1 Global physical/real biobanks market, 2017 - 2028 (USD Million)7.2.2 Tissue biobanks7.2.3 Population based biobanks7.2.4 Genetic (DNA/RNA) based biobanks7.2.5 Disease based biobanks7.2.6 Global disease based biobanks market, 2017 - 2028 (USD Million)7.3 Virtual Biobanks

Chapter 8 Biobanks Market Categorization: Application Estimates & Trend Analysis8.1 Global Biobanks Market: Application Movement Analysis, 2020 & 20288.2 Therapeutics8.3 Drug Discovery & Clinical Research8.4 Clinical Diagnostics

Chapter 9 Biobanks Market Categorization: Regional Estimates & Trend Analysis, by Products, Services, Biospecimen Types, Biobank Types, & Applications9.1 Biobanks Market Share by Region, 2020 & 2028

Chapter 10 Competitive Landscape

For more information about this report visit

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

See more here:

Global Biobanks Markets Report 2021-2028: Biobanks Continue to Evolve with New Technologies Such as NGS and Increased Focus on Genomic Medicine -...

Read more
Stem Cell Therapy Market Set to Witness Huge Growth and Competitive Outlook Anterogen Co., Ltd, Pharmicell, STEMCELL Technologies, Astellas Pharma …

This market study on Stem Cell Therapy Market covers The market study conducted in this report analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors in the industry. Also, it sheds light on the wide-ranging competitive landscape of the global Stem Cell Therapy market. It defines about the recent innovations, applications and end users of the market.The report first introduces the market basics like definitions, classifications, applications, and industry chain overview, and then industry policies and plans, product specifications, manufacturing processes, cost structures, and so on. The challenges led by the COVID-19 pandemic, leading to a decline in demand, and several initiatives taken by the government are studied in this report. The wide range of end-use applications, Heat Pumps major types, revenue, and distributors are stated. The regional analysis covers North America, Europe, APAC, Latin America, and MEA.

Stem cell therapy market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 18.66 billion by 2027 growing with a CAGR of 9.25% in the above-mentioned forecast period. The growing awareness to therapeutic potency of stem cells in disease organization will help in driving the growth of the stem cell therapy market.

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.

The key manufacturers covered in this report:

Osiris Therapeutics, Inc MEDIPOST Co., Ltd Anterogen Co., Ltd Pharmicell Co., Ltd STEMCELL Technologies Inc Astellas Pharma Inc Cellular Engineering Technologies Inc BioTime Inc Takara Bio Inc U.S. Stem Cell, Inc BrainStorm Cell Therapeutics Inc Caladrius Biosciences, Inc Athersys

Detailed Market Analysis and Insights:

The market report also covers strategic profiling of the major players in the market, all-inclusive analysis of their basic competencies, and hence keeps competitive landscape of the market in front of the client. The world class Stem Cell Therapy business report also illustrates the CAGR values for the historic years 2019, the base year 2018 and the forecast for the years 2021-2027.An international Stem Cell Therapy report identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the market for industry. For a thriving business, it is quite essential to get knowhow of consumers demands, preferences, attitudes and their changing tastes about the specific product and this report is right there to solve this purpose.

Segmentation Of Stem Cell Therapy Market:

By Technology (Cell Acquisition, Cell Production, Cryopreservation, Expansion and Sub-Culture)

By Product (Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells)

By Applications (Musculoskeletal Disorders, Wounds, Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, Other Applications)

By End Users (Therapeutic Companies, Cell And Tissues Banks, Tools And Reagent Companies, Service Compan


The Stem Cell Therapy market report comprises of several market dynamics and estimations of the growth rate and the market value based on market dynamics and growth inducing factors. For generation of an excellent market research report, principal attributes such as highest level of spirit, practical solutions, dedicated research and analysis, innovation, talent solutions, integrated approaches, most advanced technology and commitment plays a key role. The report contains reviews about key players in the market, major collaborations, merger and acquisitions along with trending innovation and business policies.

Competitive Landscape and Stem Cell Therapy Market Share Analysis

The major players covered in the stem cell therapy market report are Osiris Therapeutics, Inc., MEDIPOST Co., Ltd., Anterogen Co., Ltd., Pharmicell Co., Ltd., STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Caladrius Biosciences, Inc., Athersys., Cytori Therapeutics, Inc., Fate Therapeutics Inc., Pluristem Therapeutics Inc., Thermo Fisher Scientific., Vericel Corporation., ViaCyte, Inc, AbbVie, Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, Aastrom Biosciences, Inc., Advanced Cell Technology

To receive extensive list of important regions, ask for TOC here @

Global Stem Cell Therapy Market Scope and Market Size:-

Based on type, the stem cell therapy market is segmented into allogeneic stem cell therapy and autologous stem cell therapy On the basis of technology, the stem cell therapy market is segmented into cell acquisition, cell production, cryopreservation and expansion and sub-culture On the basis of product, the stem cell therapy market is segmented into adult stem cells, human embryonic stem cells and induced pluripotent stem cells Based on application, the stem cell therapy market is segmented into musculoskeletal disorders, wounds, injuries, cardiovascular diseases, surgeries, gastrointestinal diseases and other applications

Major Highlights from Table of contents are listed below for quick lookup into Stem Cell Therapy Market report

Important Features that are under Offering and Key Highlights of the Reports:

Detailed overview of Stem Cell Therapy Market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application, etc.

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Stem Cell Therapy Market Products

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

On the Basis of Region

The report is mainly segmented into several key regions, with sales, revenue, market share and growth rate of Stem Cell Therapy in these regions, from 2020 to 2027, covering:

U.S., Canada and Mexico in North America, Germany, France, U.K.

Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe

China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand

Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA)

Enquire Here for, Report Enquiry, Discount and Customization:

Benefits of Buying The Report:

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

More here:

Stem Cell Therapy Market Set to Witness Huge Growth and Competitive Outlook Anterogen Co., Ltd, Pharmicell, STEMCELL Technologies, Astellas Pharma ...

Read more
In the zone for liver proliferation – Science Magazine

In humans, the liver is the most regenerative solid organ, able to regrow to normal size after removal of up to 90% of the liver volume (1, 2). The liver is also distinct because it scales with body size, a characteristic that has been attributed to a hepatostat that adjusts liver size to the needs of the body (3). Identifying the cells contributing to liver homeostasis and repair could lead to therapies that can activate specific cellular compartments responsible for regeneration. On pages 906 and 905 of this issue, Wei et al. (4) and He et al. (5), respectively, find that, in mice, a subset of cells in a particular region of the liver, called midlobular zone 2, are the major contributors to hepatocyte proliferation during homeostasis and identify other hepatocyte subsets that contribute to regeneration after damage. This raises questions regarding the mechanisms that induce hepatocyte proliferation and the zonal division of labor with respect to the hepatostat.

Read more here:

In the zone for liver proliferation - Science Magazine

Read more
We have a hint it may be possible: Controversial stem cell therapy repaired injured spinal cords in 13 patients – RT

Using a somewhat controversial stem cell therapy, a joint team of Japanese and US-based researchers have successfully repaired some damage in 13 patients with spinal cord injuries (SCI).

SCIs can often cause permanent loss of movement and physical sensation from resultant nerve damage. While physical rehabilitation programs can partially improve outcomes, actual treatment and recovery of lost mobility and function is nigh on impossible. Until now, perhaps.

According to new results from a phase 2 clinical trial conducted in an experimental collaboration by scientists in Japan and the US, patients treated with an intravenous infusion of their own mesenchymal stem cells (MSCs), harvested from their bone marrow, saw significant functional improvements.

MSCs are adult stem cells with the uncanny ability to morph into numerous different cell types, affording them the ability to repair different tissues in the human body, ranging from bone and cartilage to muscle or other tissues.

In 2018, Japan fast-tracked commercial approval of the treatment, opting to forego full testing and regulatory approval despite a lack of complete data on its safety and efficacy. This was much to the consternation of the medical industry at large, and caused considerable controversy in the process.

Fast-forward to the present day and the therapy, called Stemirac, may prove revolutionary in treating non-penetrative SCIs, in which the spinal cord is damaged but remains intact.

In the trials, all 13 patients demonstrated improvements in sensory and motor function six months after they received their infusion, while more than 50 percent of the participants saw substantial improvements in motor function, including walking within a day, though for others it took weeks.

"The idea that we may be able to restore function after injury to the brain and spinal cord using the patient's own stem cells has intrigued us for years," explains neurologist Stephen Waxman from Yale University, a senior author of the study.

"Now we have a hint, in humans, that it may be possible."

Other research has examined the efficacy of injected MSCs to treat SCI, but this new method involves intravenous infusion, which operates in a different way and, so far, has no adverse effects. Still, the researchers acknowledge the limited scope of the trial, as well as the fact that it was unblinded and uncontrolled.

"Importantly, intravenously infused MSCs may affect not only the injury site, but other parts of the central nervous system including brain and blood vessels," the authors explain in their paper.

For now, they suspect the stem cells secrete neural growth factors, particularly brain-derived neurotrophic factor (BDNF), which have a restorative as well as anti-inflammatory effect. While a lot more research is needed to determine the long term safety and efficacy of the treatment, it could one day prove revolutionary.

Think your friends would be interested? Share this story!

More here:

We have a hint it may be possible: Controversial stem cell therapy repaired injured spinal cords in 13 patients - RT

Read more
One a day keeps the doctor away? Eating apples appears to boost brain function – Genetic Literacy Project

The GLP Needs Your Help

It is easier than ever for advocacy groups to spread disinformation on pressing science issues, such as the ongoing coronavirus pandemic. No, vaccines are not harmful. Yes, the use of biotechnology, GMOs or gene editing to develop antigens for treatments including vaccines are part of the solution. To inform the public about whats really going on, we present the facts and challenge those who don't. We cant do this work without your help. Please support us a donation of as little as $10 a month helps support our vital myth-busting efforts.

Visit link:

One a day keeps the doctor away? Eating apples appears to boost brain function - Genetic Literacy Project

Read more
Global Stem Cell Therapy Market Opportunities & Challenges, Threat and Affecting Factors 2020-2027||Smith and Nephew STEMCELL Technologies Inc.,…

Stem cell therapy marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 18.66 billion by 2027 growing with a CAGR of 9.25% in the above-mentioned forecast period.

Stem Cell Therapy report provides the solid foundation required to accomplish the variety of business challenges that come along. To generate this winning market research report, goals are set and primary and secondary segments are decided to get the grips with the kind of information required to achieve effective results. The report is very concise and accurate which is straight to the point and also dont omit any essential information. All the collected market data is cleaned and organized before formulating an excellent market report. The complete Stem Cell Therapy market research report has executive summary which explains the general idea of the report.

To find Exhaustive Information about Stem Cell Therapy Market, go through sample copy of this research

Key Market Competitors Covered in the Report

Osiris Therapeutics, Inc. (U.S.),MEDIPOST Co., Ltd. (South Korea),Anterogen Co., Ltd. (South Korea),Pharmicell Co., Ltd. (South Korea), Smith and NephewSTEMCELL Technologies Inc., Transentrix Surgical, Inc.Astellas Pharma Inc.Cellular Engineering Technologies Inc.BioTime Inc.,Takara Bio Inc.,U.S. Stem Cell, Inc.,BrainStorm Cell Therapeutics Inc.Caladrius Biosciences, Inc.,

Global Stem Cell Therapy Market Scope and Market Size

Stem cell therapy market is segmented on the basis of type, technology, product, applications and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

For more analysis on the stem cell therapy market request for a briefing with our analysts @

Core Objectives of Stem Cell Therapy market research

Queries Resolved In This Report:

Points Involved in Stem cell therapy Market Report:

To know more about the study @

Market Insights in the Report

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by We are content with our glorious 99.9 % client satisfying rate.


Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192

Excerpt from:

Global Stem Cell Therapy Market Opportunities & Challenges, Threat and Affecting Factors 2020-2027||Smith and Nephew STEMCELL Technologies Inc.,...

Read more